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Background
The first generation antiretrovirals that have been devel-
oped and used to treat primarily subtype B infected
patients are finally becoming available in African coun-
tries. However, the subtype B is not the dominant subtype
in Africa and the question remains if these subtypes are
susceptible to these drugs. We will here try to answer this
question by use of artificial neural networks (ANNs). We
have previously showed that, based on the physiochemi-
cal properties of the amino acids, ANNs are able to extrap-
olate predictions to non-B subtypes with high accuracy
[1].
Methods
We applied the use of these ANNs to further predict the
IC50 FC susceptibility for the most dominant subtypes in
Africa: A, C, G and CRF_AG; to the drugs: abacavir, ampre-
navir, atazanavir, didanosine, efavirenz, indinavir, lami-
vudine, lopinavir, nelfinavir, nevirapine, ritonavir,
saquinavir, stavudine, tenofovir, zalcitabine, zidovudine.
We obtained reference sequences for these subtypes from
the Los Alamos HIV sequence database. These subtypes
we used for input to the ANNs to predict the IC50 FC for
each of the above drugs. We used an unpaired t-test to
identify significant differences in mean of the IC50 FC val-
ues between B-subtype and non-B subtypes.
Summary of results
Plots of the predictions for the individual drugs and mean
for each subtype is shown in Figure 1. We found no signif-
icant difference in mean IC50 FC for subtypes C (mean =
0.74) or CRF_AG (mean = 0.87) compared to the subtype
B (mean = 1.02). But there was a significant difference
between B and A (mean = 1.18) and B and G (mean =
1.31). Drugs with a predicted IC50 FC >2-fold are for A:
zidovudine: 2.7 and nelfinavir: 2.4; C: nelfinavir 3.2; G:
amprenavir: 2.2, zidovudine: 2.5, nelfinavir: 4 and ata-
zanavir 4.1; CRF_AG: atazanavir: 2.5, zidovudine: 2.8 and
nelfinavir 3.2. Excluding these drugs from the analysis
resulted in all differences in mean IC50 FC between sub-
type B and non-B subtypes not to be significant.
Conclusion
Predictions showed significant difference between the
predicted mean IC50 FC values for the both A and G HIV-
1 subtypes compared to IC50 FC for subtype B. This is in
large driven by reduced susceptibility to amprenavir, ata-
zanavir, nelfinavir, and zidovudine and does also affect
susceptibility for C and CRF_AG subtypes. With the
majority of the drugs we did not find any reduced suscep-
tibility for the subtypes.
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